Latest Content

Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.

A reflection on shame, vulnerability and transformation, exploring how the past shapes us and how presence can help us let go and heal.

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.

AJ Wyman shares his daughter’s cancer journey and why parents caring for a child with cancer must make time for their own mental health, too.

A powerful reflection on finding hope, healing and meaning through life’s challenges, inspired by the lessons and beauty found in the sea.

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went a median of 14.3 months without their disease worsening, compared with 8.3 months with immunotherapy plus chemotherapy.

Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.

In the phase 3 ADAURA trial, 79% of patients who took Tagrisso for three years after lung cancer surgery were alive at eight years, compared with 64% of patients who received a placebo.

Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.

Twenty-three years after a breast cancer diagnosis at 39, a survivor explains why her garage gym became a place to rebuild strength.

Diagnosed with peritoneal mesothelioma at 21 and given 18 months to live, a survivor reflects on what turning 40 means nearly two decades later.

Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.

Most cancers now have at least three or four treatment approaches, and an oncologist explained how cancer heterogeneity shapes the way patients respond.